Krystal Biotech (KRYS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 14/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.87% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin
- Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
- What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders
- Why Krystal Biotech (KRYS) Is Drawing Fresh Attention
- Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x Run
- Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?
- Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
- Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS(G12C) mutations. — Future Oncol 2026 Sep 16 PMID 42745627
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Krystal Biotech.
Full KRYS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.